Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol’s New Anti-PD-1 Immunotherapy An ASCO High Point

Executive Summary

Bristol-Myers Squibb’s “anti-PD-1,” an antibody that gets between immune system T-cells out to destroy cancer cells and a cancer defense mechanism that would tie them up, caught the fancy of attendees at the American Society of Clinical Oncology annual meeting in Chicago with Phase I data indicating the drug could be safer and more effective than Bristol’s breakthrough immunotherapeutic for melanoma, Yervoy.

You may also be interested in...



Two Approaches To PD-1 Blocker Pediatric Studies Could Help Clarify Biomarker’s Role

Merck plans to enrich its Phase II study for MK-3475 with patients whose tumors express PD-L1; Bristol would take all comers in its Phase I/II trial of nivolumab.

Big Pharma Explores New Frontier Of Lung Cancer Immunotherapy

Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.

ASCO Preview: Bristol PD-1 Data Spur Hopes For Double Immunotherapy

Immune checkpoint antibodies feature prominently in American Society of Clinical Oncology annual meeting program, showing promise in a range of cancers. Bristol showcases data for Yervoy in combination with its anti-PD-1 nivolumab in melanoma, while Roche unveils extensive early results for its anti-PD-L1 MPDL3280A.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054504

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel